로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Claudin 18.2 Hot |FMC 63 Ab  |FcRn
0
장바구니가 비어 있습니다
내 장바구니
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: 홈 > FKBP12

FKBP12

요약

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKCI2,Tacrolimus Binding Protein 1A,FKBP12C,FK506 Binding Protein 1A, 12kDa,12 KDa FK506-Binding Protein,Immunophilin FKBP12,12 KDa FKBP,Rotamase,FKBP Prolyl Isomerase 1A,FKBP1,FKBP12,FKBP-12,PPIase FKBP1A,FK506-binding protein 1A,Calstabin-1,FKBP-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

제품 리스트 구매

제품> 결과 필터링
제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 종 제품 설명 구조 순도 특징
FKA-H5122 Human Human FKBP12 / FKBP1A Protein, His Tag
FKA-H5122-structure
FKA-H5122-sds

Synonym Name

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

Background

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tacrolimus Hydrate MR-4; RTU-007; LCP-Tacro; FR-900506; L-679934; FK-506MR; FK-506E; FK-506 Approved Astellas Pharma Inc Protopy, Graceptor (as hydrate), Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, 普乐可复, Advagraf, Envarsus, Modigraf, Astagraf XL, TacroBell Japan Arthritis, Rheumatoid; Colitis, Ulcerative; Conjunctivitis, Allergic; Lupus Nephritis; Coronary Restenosis; Dermatitis, Atopic; Rejection of organ transplantation; Myasthenia Gravis Astellas Pharma Inc 1993-01-01 Wounds and Injuries; Brain Death; Conjunctivitis, Allergic; Psoriasis; Amputation, Traumatic; Pulmonary Arterial Hypertension; Colitis, Ulcerative; Asthma; Surgical Wound Infection; Burns; Rejection in heart transplantation; Infertility, Female; Conjunctivitis; Nephrotic Syndrome; Coronary Restenosis; Renal Insufficiency, Chronic; Keratoconjunctivitis; Dermatitis, Atopic; Peripheral Nerve Injuries; Ocular inflammation; Encephalitis; Edema; Vitiligo; Crohn Disease; Primary Graft Dysfunction; Myasthenia Gravis; Polymyositis; Keratoconjunctivitis Sicca; Liver Failure; Reperfusion Injury; Genital Diseases, Male; Medication Adherence; Bone marrow transplant rejection; Rejection of liver transplantation; Glomerulonephritis, IGA; Dermatomyositis; Rejection of renal transplantation; Keratoplasty rejection; Rejection of lung transplantation; Renal Insufficiency; Arthritis, Rheumatoid; Kidney Diseases; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Lupus Nephritis; Rejection of organ transplantation; Dry Eye S Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Plerixafor/Tacrolimus Hydrate MRG-001(MedRegen); AMD3100+FK506 Phase 2 Clinical MedRegen LLC Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries Details
Rimiducid AP-1903 Phase 2 Clinical Ariad Pharmaceuticals Inc, Bellicum Pharmaceuticals Inc Neuroblastoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Metabolic Diseases; Prostatic Neoplasms; Osteopetrosis; Osteosarcoma; Sarcoma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Anemia, Sickle Cell; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Congenital Bone Marrow Failure Syndromes; Melanoma; Thalassemia; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Leukemia; Hematologic Neoplasms; Lymphoma, B-Cell; Neoplasm, Residual; Solid tumours; Immunoproliferative Disorders; Leukemia, Lymphoid; Lymphatic Diseases; Primary Immunodeficiency Diseases; Anemia, Diamond-Blackfan; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hemoglobinopathies; Fanconi Anemia; Neoplasms; Immune System Diseases Details

This web search service is supported by Google Inc.

totop
Call us
우리에게 전화하세요
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Email
이메일
order.kr@acrobiosystems.com
Fax
팩스
+1 888-377-6111
Address
주소
서울 성동구 왕십리로10길 6 서울숲비즈포레 703
회사명
아크로바이오 주식회사
사업자 등록번호
186-88-02858
대표자
CHEN YIDING
사업장주소
서울특별시 송파구 중대로12길 10-20, 1층 셀렉티드송파(가락동)
linkedin twitter facebook youtube

문의

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap